The protein LEM promotes CD8(+) T cell immunity through effects on mitochondrial respiration by Okoye, I et al.
	   1	  
The protein LEM promotes CD8+ T cell immunity through effects on 
mitochondrial respiration 
 
Isobel Okoye1*, Lihui Wang, 1*, Katharina Pallmer2,, Kirsten Richter2,  
Takahuru Ichimura3 Robert Haas4, Josh Crouse2, Onjee Choi1, Dean Heathcote1, Elena 
Lovo1, Claudio Mauro4, Reza Abdi3, Annette Oxenius2, Sophie Rutschmann1^ and 
Philip G Ashton-Rickardt1,3. 
 
1Section of Immunobiology, Division of Inflammation and Immunology, Department 
of Medicine, Faculty of Medicine, Imperial College London, Exhibition Road, 
London SW72AZ. UK. 
2Institute of Microbiology, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, 8093, Zurich, 
Switzerland. 
3Transplantation Research Center, Brigham and Women’s Hospital, Harvard Medical 
School, 221 Longwood Avenue, Boston MA 02215. USA.  
4	  William Harvey Research Institute, Barts and The London School of Medicine and 
Dentistry, Queen Mary University of London, London EC1M 6BQ, UK 
	  * These authors contributed equally 
 
^ Current address: Section of Molecular Immunology, Division of Inflammation and 
Immunology, Department of Medicine, Faculty of Medicine, Imperial College 
London, Du Cane Road, London W12 0NN. UK. 
 
 
 
	   2	  
Protective CD8+ T cell-mediated immunity requires a massive expansion in cell 
number and the development of long-lived memory cells.  Using forward genetics in 
mice, we identified an orphan protein named Lymphocyte Expansion Molecule 
(LEM) that promoted antigen-dependent CD8+ T cell proliferation, effector function 
and memory cell generation in response to infection with lymphocytic 
choriomeningitis virus. Generation of LEM-deficient mice confirmed these results. 
Through interaction with CR6 interacting factor (CRIF1), LEM controlled the levels 
of oxidative phosphorylation (OXPHOS) complexes and respiration resulting in the 
production of pro-proliferative mitochondrial Reactive Oxygen Species (mROS). 
LEM provides a link between immune activation and the expansion of protective 
CD8+ T cells driven by OXPHOS and represents a pathway for the restoration of 
long-term protective immunity based on metabolically modified CTL.  
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Cytotoxic CD8+ T cells (CTL) are a central arm of the immune system responsible for 
protection from intracellular viruses and cancer because they kill infected or 
transformed cells (1). Since chronic virus infection (2) and cancer (3) are wide spread 
diseases it is clear that CTL-immunity often fails. A major reason for this failure is 
because high viral (4, 5) or tumor (6-8) load results in either deletion or functional 
inactivation (known as immune exhaustion) of CTL.  The result is failure in both 
short-term CTL immunity and immunological memory because memory CD8 T cell 
development is blocked (9). Impaired expansion is an important cause of deletion and 
immune exhaustion and results in the failure to produce sufficient numbers of 
protective CTL and memory cells (5). 
 
 
Retro mutant mice have increased immunity to chronic viral infection 
 
Infection of wild-type C57BL/6 mice with the clone 13 variant of lymphocytic 
choriomeningitis virus (LCMV C13) is an established model for human chronic viral 
infection resulting in a massive viral load that causes both deletion and immune 
exhaustion of CTL and a block in memory CD8 T cell development (10).  
 
We examined the CTL response to LCMV C13 infection after germ-line mutagenesis 
to identify mutants with enhanced immunity. To this end, 430 third-generation (G3) 
ethyl-N-nitrosourea (ENU)-induced germ-line mutants were produced in a C57BL/6J 
background (11). G3 mice were infected with LCMV C13 and after 8 days the level 
of LCMV-specific CD8 T cells measured in the spleen by staining with a tetramer for 
the np396 LCMV peptide and flow-cytometry (12). Three independent germ-line 
transmissible modifications, which resulted in increased levels of LCMV-specific 
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CD8 T cells were isolated, of which one (a semi-dominant) was bred to homozygosity 
(Fig. S1a). We named this strain Retro.  
 
Homozygous Retro mutant mice showed a 10-fold increase in CD8 T cells specific 
for LCMV np396 peptide compared to wild-type (WT) and a smaller but significant 
increase in the number of CTL specific for the gp33-LCMV peptide (Fig. 1 a, b). 
Compared to WT mice, a smaller percentage of Retro mutant CTL expressed the 
Programmed Cell Death-1 (PD-1) immune exhaustion marker (5) (Fig. 1c). However, 
Retro mutant mice still harbored increased numbers of PD-1+ np396+ CD8+ cells 
compared to WT  (Fig. 1d). In addition, Retro mutant CTL exhibited increased 
functionality: there was increased CTL activity in ex vivo killing experiments (Fig. 
1e), increased exocytosis of cytotoxic granules  (11) (Fig. 1f), and increased 
production of the cytokine interferon (IFN)-γ (Fig. S1b). The increase in CTL 
immunity resulted in a 106-fold decrease in LCMV C13 titer in the spleens of Retro 
mutant mice on day 8 after infection compared to WT (Fig. 1g). The increase in CTL 
activity was a function of cell number (Fig. S1c).  
 
All Retro mutant mice succumbed to LCMV C13 infection after 14 days whereas all 
WT mice had survived (Fig. 1h). Retro mutant death is presumably a consequence of 
elevated CTL-mediated cytolysis resulting in the fatal loss of vascular integrity (13). 
Despite an increase in activated phenotype T cells (Fig.S2), viability, blood 
development and autoimmunity in Retro mutant mice was normal (Fig. S3 and Tables 
S1-S3). In vivo BrdU labelling indicated that np396+ CD8+ cells underwent increased 
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proliferation after LCMV C13 infection of Retro mutant mice (Fig. 1i). The increased 
number of antigen-specific CD8 T cells in LCMV C13-infected Retro mutant mice is 
likely due to increased proliferation of these cells. 
 
 Adoptive transfer of Retro mutant CD8 T cells (14), showed that the phenotype of 
increased CTL-immunity resides in the CD8 T cell compartment (Fig. S4a-d).  The 
phenotype of Retro mutant mice also extended to anti-tumor responses. After 
challenge with B16 F10 melanoma cells, Retro mutant mice harbored 3-fold more 
CTL (Fig. 2a) and 4-fold fewer tumors (Fig. 2b, c).  
 
Retro mutant mice have increased memory T cell development 
After acute infection of Retro mutant mice with LCMV Armstrong there was an 
increase in the clonal burst size of both np396+ CD8+ and gp33+ CD8+  cells (Fig. 2d, 
e) compared to WT.  Longitudinal analysis in the blood revealed a corresponding 
increase in the number of LCMV-specific CD8 T cells during the memory phase in 
Retro mutant mice (15). After 70 days, there was a 4-fold increase in the number of 
LCMV-specific central memory T CD8 cells (Tcm) in the spleen as identified by the 
CD62L+ CD127+ CD8+ cell surface phenotype (16) (Fig. S4e,f).  
 
We boosted mice with a second dose of LCMV Armstrong and measured the 
expansion of secondary CTL during the memory response. The numbers of secondary 
CTL were about 10-fold higher compared to WT (Fig. S4g,h) indicating that  Retro 
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mutant mice have an enhanced memory phenotype.  During acute immune responses 
the pool of CTL contains not only short-lived effectors but also memory cell 
precursors (17, 18). The increase in the total number of CD8 T cells resulted in an 
increase in the number and percentage of both memory cell precursors and short-lived 
effectors in Retro mutants compared to WT (Fig. S5).  Therefore the Retro mutation 
increases the level of both primary short-lived effectors and Tcm by facilitating a 
global increase in the expansion of antigen-activated CD8 T cells.  
 
The Retro mutation identifies Lymphocyte Expansion Molecule 
We used high-throughput exome sequencing (19) to identify the Retro mutation. 
Comparison with the reference C57BL/6J genome identified several homozygous 
single nucleotide variants (SNV) in homozygous Retro mutant mice (Fig. S6a).  Upon 
re-sequencing and comparison with the Charles River sub-strain of C57BL/6J used 
for our ENU mutagenesis, four homozygous SNVs were identified as being 
associated with Retro homozygous mutant mice. Only one homozygous SNV 
correlated with the Retro homozygous phenotype (Fig. S6b).  This was an A to G 
transition of nucleotide 1304 (A1304G) in exon 2 of the BC055111 gene on 
chromosome 4 (Fig. S7a).  BC055111 encodes an orphan protein with no significant 
homology to any other mouse protein (BLASTP: E value > 0.38). The BC055111Retro 
allele (R) was semi-dominant for increased CTL immunity to LCMV C13 (Fig.S7b-
d).  
 
We generated C57BL/6 mice with a BC055111 knock-out (KO) allele (20) (Fig. S8).  
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Homozygosity for the BC055111 KO allele results in embryonic lethality and so we 
used heterozygous KO mice to validate the gene candidate (12). There was decreased 
BC055111-encoded protein in CTL from heterozygous BC055111 KO mice compared 
to WT (Fig. 3a,b).  We observed decreased np396+ CD8+ expansion (Fig. 3c), 
increased LCMV titer (Fig. 3d) and decreased CTL activity (Fig. 3e) in BC055111 
W/KO compared to BC055111W/W mice. Therefore BC055111 directly controls CTL 
immunity to LCMV .  We named the BC055111 encoded orphan protein Lymphocyte 
Expansion Molecule (LEM).  
 
The Retro mutation stabilizes Lem mRNA  
The kinetics of Lem mRNA accumulation in Retro mutant CD8 T cells after LCMV 
C13 infection was increased compared to WT (Fig. 3f). The increased level of Lem 
mRNA was also observed when transcription was inhibited by actinomycin D, 
indicating that the Retro mutation stabilized Lem mRNA in CD8 T cells (Fig. 3g).  
 
Lem mRNA contains introns in the 3’ un-translated region (3’-UTR), which may 
make it susceptible to Nonsense mediated decay (NMD) (21). This was confirmed 
when blockade of NMD by emetine increased the stability of wild-type Lem mRNA 
(Fig. 3g).  The Retro mutation is predicted to abolish an Alternative splice 
factor/Splice factor 2 (ASF/SF2) binding site in Lem (12), which is thought to be 
required for NMD (22).  Immunoprecipitation (IP) confirmed decreased levels of SF2 
associated with Retro mutant Lem message (Fig. 3h) in cells with normal SF2 levels 
(Fig. 3i).  This suggests that the A1304G mutation in Retro mutant mice partially 
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protects Lem mRNA from NMD resulting in stabilization. The Lem open-reading 
frame (ORF) harboring the Retro A1304G mutation was no better than WT ORF at 
driving interleukin (IL)-2 induced proliferation of T cells (Fig. S9  and Fig. 3j). 
Therefore, the increased expression of Lem rather than any qualitative alteration in 
protein activity is responsible for the phenotype of Retro mutant mice. We conclude 
that WT LEM is a positive modulator of CTL expansion that is up-regulated in Retro 
mutant mice.  
 
The Retro mutation increases LEM expression  
LEM protein was up-regulated in total CD8 T cells after LCMV C13 infection with 
Retro mutant mice displaying increased kinetics compared to WT (Fig. 4a,b).  
Intracellular staining (ICS) (Fig. S10) indicated that LEM expression was specific for 
activated CD8 T cells (CD44hi CD62Llo CD8+) and was elevated in Retro mutant cells 
(Fig. 4c,d). LEM was up-regulated 2 days after LCMV C13 infection despite a low 
frequency of CD8 cells expressing LCMV-specific TCRs  (Fig. S11a and Fig 4a,c). In 
addition to stimulation through the TCR (via anti-CD3 antibody) (Fig. 4e), treatment 
with either IL-2 (Fig. 4f) or IL-15 (Fig. 4g) resulted in LEM up-regulation, which was 
enhanced in Retro mutant CD8 T cells (Fig. 4e-g). Therefore, LEM expression can be 
induced by bystander activation by pro-proliferative cytokines as well as antigen-
dependent TCR signals. The level of LEM controlled the levels of Retro mutant CD8 
T cells both in vivo  (Fig. S11b-e) and in vitro (Fig. S12). PD-1 up-regulation by 
Retro mutant CTL was un-affected in vitro after TCR-stimulation suggesting that 
LEM does not directly down-regulate PD-1 expression (Fig. S11f,g).  
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Functional equivalence of human LEM 
C1ORF177 encodes the human homologue of LEM (BLASTP: 72% of complete 
amino acid identity with mouse LEM, E value = 0), which is up-regulated in activated 
human CD8 T cells (Fig. 4h,i). Ectopic expression of human-LEM resulted in about a 
15-fold increase in the expansion (Fig. 4j).  Therefore, LEM can modulate CD8 T cell 
expansion in man as well as mice. 
 
LEM interacts with CRIF1 to control the activity of OXPHOS proteins  
Analysis of LEM amino acid sequence predicts the presence of at least two 
intrinsically unstructured (IU) protein domains (12, 23). Therefore we investigated 
whether LEM modulates CD8 T cell proliferation through specific protein: protein 
interactions. Yeast two-hybrid  (Y2H) analysis identified 9 different LEM-interacting 
proteins (24)) (Fig. S13). Co-immunoprecipitation (co-IP) with anti-LEM antibody 
(Fig. S10), demonstrated that one target – CR6 interacting factor (CRIF1) interacts 
with LEM in CTL (Fig. 5a, b).   
 
CRIF1 is required for the translation and insertion of oxidative phosphorylation 
(OXPHOS) polypeptides into the inner membrane of mitochondria after they emerge 
from the 39S subunit of the mitoribosomes (25). Confocal immunofluorescence 
microscopy (CIM) revealed that LEM co-localizes with CRIF1 in CTL (Fig 5c,d and 
Fig. S14).  Both LEM and CRIF1 were localised to mitochondria by co-staining with 
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the mitotracker red dye (Fig. S15 and S16).  Co-IP localized LEM to the 
mitoribosome by revealing an association with the 39S subunit protein MRPL23 and 
several OXPHOS proteins such as NADH ubiquinone oxidoreductase chain 1 (ND1), 
ubiquninol cytochrome c oxidoreductase chain 2 (UQCRC2) and cytochrome c 
oxidoreductase chain 1 (COX1) (25) (Fig. 5e). The OXPHOS protein ATP synthase α 
subunit 1 (ATP5A1) does not require CRIF1 for translation and did not co-IP, 
suggesting that interaction of LEM with OXPHOS proteins is via CRIF1. Through its 
interaction with CRIF, LEM is part of a complex that mediates the translation and 
insertion of OXPHOS proteins into the mitochondrial inner membrane. 
  
Retro mutant CTL harbored increased levels and heterozygous LEM KO CTL 
reduced levels of OXPHOS proteins (Fig. 5f,g). Immuno-capture confirmed that the 
specific activities of OXPHOS complexes were elevated in Retro mutant CTL (Fig. 
5h,i); although LEM did not affect the expression of Oxphos genes or the number or 
mass of mitochondria (Fig. S17a-c). Therefore, LEM controlled the activity of 
OXPHOS complexes by most likely facilitating the production of sub-unit proteins.  
 
As was observed in CRIF1 KO cells (25), when we knocked down Crif1 mRNA (Fig. 
S18a-c), OXPHOS specific activity was reduced (Fig. 5j,k). Knock-down of Crif1 
message in Retro mutant CTL also abolished the increases in OXPHOS activity due 
to LEM up-regulation. We conclude that LEM interaction with CRIF1 within 
mitochondria determines OXPHOS activity.  
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CRIF1 is required for cell proliferation during embryo development (26). Crif1 
message knock-down resulted in the impaired proliferation and expansion of anti-
LCMV CTL (Fig S18 d,e). The increase in CTL expansion caused by LEM up-
regulation required CRIF1 expression because Crif1 message knock-down diminished 
the increased expansion of Retro mutant CTL. We conclude that LEM requires 
interaction with CRIF1 to drive the expansion of CTL. 
 
LEM is a positive modulator of mitochondrial ROS-driven proliferation 
We examined the consequences of LEM control of OXPHOS activity on CTL 
metabolism and expansion.  Oxygen consumption studies demonstrated that Retro 
mutant CTL had significantly higher respiratory levels compared to WT (Fig. 6a) (27) 
but glycolysis was not increased (Fig. S17d). Conversely, respiratory activity (Fig. 
6b) of LEM heterozygous KO CTL but not glycolysis (Fig. S17e) was decreased.  
 
OXPHOS results in the production reactive oxygen species (ROS) through stepwise 
reduction of O2 (27). The modulation of OXPHOS by LEM resulted in altered 
production of mROS. Staining with the redox sensitive dye MitoSOX red revealed 
that compared to WT, Retro mutant CTL had increased levels of mitochondrial ROS 
(mROS) and LEM heterozygous KO CTL had decreased mROS (Fig.6c). The 
production of mROS is required for the activation and expansion of T lymphocytes 
(27). Injection of Retro mutant mice with the antioxidant MnTBAP (28) reduced the 
level of mROS in CTL (Fig. 6d) resulting in decreased proliferation (Fig. 6e) and 
expansion of CTL  (Fig. 6f) with a corresponding increase in LCMV C13 titer (Fig. 
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6g). We conclude that mROS resulting from OXPHOS activity drives expansion and 
CTL immunity in Retro mutant mice.  
 
We have used unbiased forward genetics to discover LEM at the heart of a pathway 
that, when up-regulated not only restores CTL immunity to chronic viral infection and 
tumor challenge but also increases memory cell development. Although other 
molecular interventions either restore primary CTL immunity (5) or divert 
development towards the memory lineage (29) the LEM pathway is important 
because it controls the expansion of both short-term effectors and memory cells (9). 
Up-regulation of LEM in Retro mutant mice increased both the overall number of 
CTL and also the number of PD-1+ CTL. Therefore LEM therapy has the potential to 
both globally expand CTL and to increase the number of PD-1+ CTL available for de-
repression by anti-PD-1 antibodies (8).  
 
At the peptide tunnel exit of 39S mitoribosomes, LEM is likely recruited by CRIF1 to 
facilitate the insertion of OXPHOS polypeptides into the inner mitochondrial 
membrane thereby controlling OXPHOS activity (25) (Fig. S19). We propose that 
CTL expansion and memory cell development are controlled by mROS produced 
after the up-regulation of LEM upon immune activation (27, 30) 
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FIGURE LEGENDS 
Figure 1. Retro mutant mice exhibit enhanced CD8 T cell responses to chronic 
LCMV infection. a. Flow cytometry on spleen cells from day 8 post infection (p.i.) 
with LCMV C13 of wild-type (WT) and Retro homozygous mutant (R) mice. 
Staining with tetramers, refolded with either np396 or gp33 peptides, and PD-1 is 
shown (% next to gate) on CD8+ gated cells. b. Number of tetramer+ CD8+ 
splenocytes on day 8 p.i. c. % PD-1+ of tetramer+ CD8+ splenocytes on day 8 p.i. d. 
Number of PD-1+ tetramer+ CD8+splenocytes on day 8 p.i. e. % specific CTL lysis 
from Cr51-release assays for splenocytes on day 8 p.i. .  f. Number of CD107α+ CD8+ 
splenocytes on day 8 p.i. g. Titer of LCMV C13 in the spleen on day 8 p.i. h. Kaplan-
Meier survival graph after LCMV C13 infection. i. % BrdU+ of np396+ CD8+ 
splenocytes on day 8 p.i. Mean ± sem N=6-12 mice.  *** p<0.0001, ** p<0.0005, * 
p<0.001. Two-tailed student t-tests were used for all expect Geha-Breslow-Wilcoxon 
that were used for survival curves. Each data set is representative of at least 3 
individual experiments.  
Figure 2. Retro improves immunity against tumors and acute viral infections 
Mice were injected i.v. with B16 F10 melanoma cells. a. % CD3+ CD8+ CD44hi cells 
from lungs day 35 p.i. b. Foci of melanomas in the lung on day 35 p.i.. c. Number of 
melanomas per lung on day 35 p.i. Mice were infected with LCMV Armstrong. Mean 
% of (d) np396+ and (e) gp33+ CD8+ peripheral blood leukocytes (PBL). Mean ± sem, 
N=6-10 mice. *** p<0.0001 Two-tailed student t-tests were used for all. Each data set 
is representative of at least 3 individual experiments.  
 
	   19	  
 Figure 3. Retro mutation identifies LEM. BC055111W/W and BC055111W/KO mice   
were infected with LCMV C13 a. Western blot on CTL for BC055111 (49kD) on 
total CD8 T cells from the spleen on day 4 p.i. b.  Bar graph of BC055111 signal 
strength from a. BC055111W/W and BC055111W/KO mice were infected with LCMV 
C13. c. Number of np396+ CD8+ splenocytes on day 8 p.i. d.  LCMV titer in the 
spleen on day 8 p.i. e. % specific CTL lysis from Cr51-release assays for splenocytes 
on day 8 p.i.. f. Bar graph for mean Lem mRNA in total CD8 T cells from the spleens 
of WT or R mice after infection with LCMV C13. Level of mRNA normalised to the 
t=0 WT level. j.  Bar graphs for mean Lem mRNA in CD8 T cells cultured for 3 days 
in cytokines then incubated with actinomycin D or emitine. Level of mRNA 
normalised to the t=0 WT level. a-g mean ± sem, N=6 mice. Each data set is 
representative of at least 3 individual experiments. h.  Bar graphs for mean relative 
Lem or Gapdh mRNA from 2 independent immunoprecipitation experiments 
performed on N=2 mice each time. mRNA levels are relative  to WT and are from 
CD8 T cells cultured for 3 days in cytokines. i. Western blot for SF2 (27kD) after 
immunoprecipitation in h. m.  Mean number of GFP+ CTLL-2 cells cultured in IL-2 
(N=4 wells) from 3 independent transductions with MIGR1 alone (V-black), or 
MIGR1 encoded Lem ORF (WT- blue or R- red sequence).  *** p<0.005, ** p<0.01, 
* p<0.05. Two-tailed student t-tests were used. 
 
Figure 4. The Retro mutation increases LEM expression. Mice were infected with 
LCMV C13.  a. Western blots for LEM (49kD) on total CD8 T cells from the spleen. 
b. Bar graph of signal strength from a. b. Mean Fluorescence Intensity (MFI) after 
staining with anti-LEM antibody in gated (c) CD44hi CD62Llo CD8+ or (d) CD44lo 
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CD62Lhi CD8+ splenocytes after infection with LCMV C13.  Or on total CD8 T cells 
that were activated in vitro with either (e) anti-CD3/CD28, (f) IL-2 or (g) IL-15. a-g 
mean ± sem, N=6 mice h. Western blots for hLEM, 49kD on anti-CD3/CD28 
activated human CD8 T cells. i.  Bar graph of signal strength from h. i. Mean number 
of GFP+ human CD8 T cell blasts (N=4 wells) after 3 independent transductions with 
MIGR1 alone (V-black), or MIGR1 encoded hLEM ORF (blue).  *** p<0.0001, ** 
p<0.0005, * p<0.001. Two-tailed student t-tests were used. Each data set is 
representative of at least 3 individual experiments.  
 
Figure 5. LEM interacts with CRIF1 to control the activity of OXPHOS proteins 
WT and R mice were infected with LCMV C13 and on day 4 p.i. total CD8 T cells 
purified. a Western blots directly on cell extracts (input) or after immunoprecipiation 
for LEM (LEM: 49kD; CRIF1 25kD; β actin 42kD). b. Bar graph of signal strengths 
from a. c. CIM from staining with antibodies against LEM (red) or CRIF1 (green). 
Nuclei stained with DAPI (blue). Examples of co-localization (yellow) are indicated 
by arrows. Bar=2.5µm. d. Co-localization of LEM and CRIF1 as measured by 
Pearson’s correlation coefficient in multiple optical cell slices (N=62). Mean = 0.68  ± 
0.11. WT mice were infected with LCMV C13 and on day 4 p.i. total CD8 T cells 
purified. e. Western blots directly on cell extracts (input) or after immunoprecipiation 
with LEM antibody or with control rabbit IgG (MRPL23-18kD, ND1 36kD, COX1 
57kD, ATP5A1 60kD). LemWT/WT, LemR/R or LemWT/KO mice were infected with LCMV 
C13 and on day 4 p.i. total CD8 T cells purified. f. Western blots for OXPHOS 
proteins (UQCRC2 49kD.) g. Bar graph of signal strength from f. WT and R mice 
were infected with LCMV C13 and on day 4 p.i. total CD8 T cells purified. h. 
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Immunocapture-enzyme assays for OXPHOS complexes I and IV. i Bar graphs for 
mean specific activity (signal strength /mg protein) from h.  Donor CD8 T cells 
harboring vector alone of Crif1-AS were purified from WT recipient mice on day 
4p.i. with LCMV C13. j. Immunocapture-enzyme assays for OXPHOS complexes I 
and IV. k. Bar graphs for mean specific activity from j. mean ± sem N=6 mice. *** 
p<0.005, ** p<0.01, * p<0.05. Two-tailed student t-tests were used. Each data set is 
representative of at least 3 individual experiments. 
Figure 6.  LEM controls production of mitogenic mROS. LemWT/WT, LemR/R or 
LemWT/KO mice were infected with LCMV C13 and on day 4 p.i. total CD8 T cells 
purified from the spleen. a and b.  Oxygen consumption rate (OCR) after sequential 
injection of oligomycin, FCCP and antimycin A/rotenone. c. LemWT/WT, LemR/R or 
LemWT/KO mice were infected with LCMV C13 then on day 8 p.i. np 396+ CD8+ 
splenocytes were gated then the MFI of MitoSOX red staining determined. R mice 
were infected with LCMV C13 then over the course of 8 days injected with  
MnTBAP or not. Gated np 396+ CD8+ splenocytes were examined on day 8 p.i.  for d. 
MitoSOX red staining  and e % BrdU-positive cells. In the same spleens, f. Number 
of tetramer-positive cells. g. Titer of LCMV. Mean ± sem. For a-f N= 6 mice and g 
N=9 mice. ***P<0.001, ** P<0.005, * P<0.01.  Two-tailed student t-tests were used. 
Each data set is representative of at least 3 individual experiments. 
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Materials and Methods 
 
Mice  
Retro mutant mice were generated in a C57BL/6J background. C57BL/6J and 
C57BL/6J Thy1.1 congenics, were purchased from Charles River, (Lille, France) and 
bred in Central Biomedical Services (Imperial College London, London, U.K.). Mice 
were kept under specific pathogen-free conditions in individually ventilated cages. All 
animal procedures have been authorized in a British Home Office Animals Act License 
(PPL70/6490), or in accordance with the guidelines of the animal experimentation law 
(SR 455.163; TVV) of the Swiss Federal Government (animal experimentation number 
127/2011) or the Institutional Animal Care and Use Guidelines of Brigham and Women’s 
Hospital, Harvard Medical School. The N-ethyl-N-nitrosourea (ENU) mutagenesis was 
performed as previously described (11). 
The Retro phenotype was identified in ENU G3 mice as the level of np396+ CD8+ 
cells being > 6-times higher than littermate controls. Additional G3 mice were generated 
from the original G1xG2 breeding pair then intercrossed to produce G4 mice, which were 
then set up in breeding pairs. G4 mice in breeding pairs that gave >20 consecutive Retro 
phenotype G5 mice were each designated as being homozygous for the Retro mutation.  
Back-crossing of G4 Retro homozygous mutant to C57BL/6 wild-type controls revealed 
that the Retro phenotype in inherited in semi-dominant fashion with heterozygous mice 
exhibiting an intermediate phenotype for np396+ CD8+ level compared to wild-type and 
Retro homozygous mutant (Fig. S1a).  
Mice harboring the BC055111tm1a(KOMP)Wtsi allele (KO first_condition_ready_40636) 
were obtained from the NIH Knock-Out Mouse Project (KOMP) Repository at UC Davis 
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(www. knockoutmouse.org). This allele generates a null allele through splicing to a lacZ-
trapping element contained in the targeting cassette (20). Targeted JM8.4 C57BL/6N ES 
cells were verified by genomic sequencing across the locus harboring the targeting vector 
and flanking endogenous regions (MGI: 2681853) and by long-range PCR using primers 
specific for vector sequence (5’-CAC ACC TCC CCC TGA ACC TGA AAC-3’ and non-
vector genomic sequence outside the homology region (5’-CAA GAG CAA GCA GCT 
CCT CAA GAT GAC-3’) on two clones (EPD0132_1_C01 and EPD0132_1_H01) (31) 
(Fig S8). Chimeric mice were generated by microinjection of ES cells (black) into 
BALB/c (albino) blastocyst then germ-line transmission verified after backcrossing to 
C57BL/6J mice and PCR. Intercross of mice heterozygous for the BC055111tm1a(KOMP)Wtsi  
allele  (KO allele) failed to generate any progeny homozygous for the mutation (n=47 
progeny; 4 separate breeding pairs).  Therefore heterozygous BC055111 KO mice were 
used for experiments.  
 
LCMV infections 
 
Mice were infected with either LCMV C13 (106 plaque forming units (pfu) (i.v.), or 
LCMV Armstrong (primary infection- 2x105 pfu i.p. or secondary infection- 106  pfu i.p). 
LCMV titer was measured in the spleen using a quantitative (Q)-PCR method to detect 
LCMV gp33 mRNA calibrated by standard curves with LCMV gp33 gene plasmid (32). 
For in vivo antioxidant experiments MnTBAP  (5mg/kg) was injected (i.p) on day 0 at the 
same time as LCMV C13 then every day for 8 days (28).   
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Immunological Assays 
 
Flow-cytometric analysis was performed after antibody and tetramer staining of 
lymphocytes (11).  For intracellular staining (ICS), first cells were stained for surface 
markers then fixed and permeabilised using the BD intracellular cytokine staining kit 
using manufacturer’s recommendations. To measure T cell proliferation, mice were fed 
0.8 mg/ml BrdU in drinking water on day 6 of infection and analyzed on day 8.  For 
adoptive transfer experiment, total CD8 T cells  (Thy1.2+) were purified from pooled 
splenocytes from several mice (donor) using anti-CD8 magnetic beads (Miltenyi) then 
transferred (107) to C57BL/6 thy1.1+ recipients by i.v. injection (14). The level of donor 
thy1.2+ np396+ CD8+  cells were determined by antibody and tetramer staining.  Anti-
LCMV CTL activity of splenocyte populations was measured using standard Cr51- 
release assays (effector to target (E/T) ratio of 10:1) with EL4 pulsed with np396 
peptide(33). For in vitro PD-1 up-regulation, CD8 T cells (106/ml) were incubated for 3 
days with plate-bound anti-CD3 antibody (10µg/ml overnight binding) (34). For in vitro 
stimulation for proliferation studies, CD8 T cells (106/ml) were incubated for 3 days with 
plate bound anti-CD3 (3µg/ml overnight binding) and anti-CD28 (6µg/ml overnight 
binding). The level of mROS was measured by staining np396+CD8+ cells with MitoSOX 
red (Molecular Probes) on day 8 after infection with LCMV C13(27).  
To generate anti-LEM antibodies first DNA corresponding to LEM amino acid 24-
383 (M.W. 42kD) was amplified by PCR (incorporating N-terminal 10xHis tag primers: 
F 5’-TTA AGA AGG AGA TAT ACC ATG GGT TCT GAT AAG ATT CAC CAC 
CAT CAT CAC CAT CAT CAC CAC CAC GGC GTC-3’; R 5’-AAT CTG ACG CCT 
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TCG CTC GAT TGG AGC CAC CCG CAG TT CGA-3’) then cloned into the p2N E. 
coli expression vector.  The region of the LEM between the amino acids 24-383 was 
expressed as a fusion protein with a N-terminal 10x His tag then purified on Ni-columns 
using standard procedures. Rabbits were immunized with rLEM (0.2mg in Complete 
Freund’s Adjuvant then 2 boosts of 0.1mg in Incomplete Freund’s Adjuvant) then anti-
LEM antibodies affinity purified using the immunizing antigen immobilized by CnBr 
cross-linking.   Anti-LEM was used at 1µg/ml and goat anti-rabbit IgG-APC used at 
1/1000 dilution (LifeTechnologies).    
 
Melanoma Challenge  
 
Mice were injected (i.v.) with B16-F10 melanoma cells (6)(C57BL/6; American 
Tissue Culture Collection) (3x105) then after 5 weeks pulmonary melanoma metastases 
were analyzed in the lungs. The entire lung was digested and purified on a ficol gradient 
and the % of CD3+ CD8+ (CTL) from gated lymphocytes determined (6).  
 
Genomic analysis 
 
Exome sequencing was performed on genomic DNA (5µg) from Retro homozygous 
mutant mice. Exon capture (Agilent Sure Select All Exon 50 MB kit), fragment library 
construction and next generation  sequencing (NGS) (paired-end 50 x 35 bases 2 quads 
per sample using the SOLiD v4 platform) were performed by Edge Bio. Average read 
lengths were 42.5± 7.5bp with 493,715,014 reads resulting in 18,687,888,095 total bases. 
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Of this sequence, 66.7%  (1256 Mb) was mapped to the reference M. Musculus (mm9) 
(C57BL/6J strain) genome giving on average 33.7 x coverage of the mouse exome 
(37Mb).  Using DNANexus cloud based data analysis, homozygous nucleotide variants 
caused by substitution or insertion/deletion (INDEL) were identified (coverage was 5-80 
reads).   
Homozygous nucleotide variants were amplified from genomic DNA by PCR using 
the JumpStart REDtaq ReadyMix (Sigma). PCR samples were purified by QIAquick 
PCR Purification Kit (Qiagen) then sequenced (MRC CSC Genomics Core Laboratory, 
Imperial College London) and the data analysed with Sequencher software (Gene Codes 
Corporation). Primers used were: Scn9a: Forward (F): 5’-CCC TAT TCT TTC CCT 
CCC ATC-3’;Reverse (R):5'-GTT GTT GGG ATC CGC TGT TC-3’. Ppig F: 5’-CAA 
GAG ATG CAG AGA GCT CAG-3’R: 5’-CTG ATG TCT CTC TCT TTG CTT TC-3’. 
BC055111 F: 5’-GAA GCA GAT CCA AAG TGA CAT TC-3’R: 5’-GAG TTT ATCA 
AAC ATC TGG AGC-3’. SemaN F: 5'-AAC CTT CTC TTC TGC TTT CTT TG-3' 
R: 5'-GTC TGG CTT TCT ACT TGA CAC AC-3'. Itpr1 F: 5’-CAA AGA GCT TGA 
CAG TCC CTC-3'; R: 5’-ATT CCA CAG AAA TAT GAG CAC TG-3’. Zc3h4 F:  5’- 
CAC AGA TGT TGG CTG ATG ATG-3' R: 5’- GGA CAA TAT ACT CAC CTC ACG 
C-3’. Entpd3: 5’- CAC TGT TTG CTC TAA GGA GTG C -3’R: 5- GAA AGT TGC 
TCT TGG CTG TTT C-3’Dux F: 5’-CTC AAA GAG GTC CAT CAG AGG C-3’; R: 5’-
GTC TTG ATC TTG AGC TGT GGG-3’.  
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Gene Function and Expression Analysis 
 
Synthetic genes encoding BC055111 (wild-type and Retro mutant sequences), 
C1ORF177 and Crif1 open reading frames (ORF) preceded by a mini gene encoding 
3xFLAG epitope tag were assembled from oligonucleotides and PCR products (Gene 
Art). Fragments were cloned into the MIGR1 retroviral vector using Xho1 and EcoR1 
cloning sites in the forward (sense) and reverse (antisense) orientations. Retroviruses 
were packaged for transduction of mouse or human cells (35). CTLL-2 cells were 
cultured with rIL-2 50U/ml in RPMI-10% FBS then the number of GFP+ cell measured 
over time. For NMD and validation of CRIF1 function experiments, magnetic bead sorted 
CD8 T cells (106/ml) from wild-type or Retro mutant mice were cultured in IL-2, IL-7, 
IL-15 cytokines  (all 100ng/ml eBiosceinces). For Lem mRNA stability experiments, 
NMD was inhibited by incubation with emetine (10h at 100µg/ml) and transcription 
inhibited by actinomycin D (4h at 2µg/ml) after 3 days of culture (21). For CRIF1 
function experiments, CD8 T cells were transduced with MIGR1-Crif1-AS or MIGR1 
vector alone retrovirus on day 2 (35) and on day 4 adoptively transferred to C57BL/6 
recipients (5x106 GFP+ cells per mouse). Recipient mice were infected with LCMV C13 
and the number of GFP+ CD8+ cells measured in the spleen after 8 days.  Human CD8 T 
cells were purified from normal donor peripheral blood mononuclear cells (PBMC) by 
magnetic bead sorting then cultured (106/ml) with anti-CD3 antibody (OKT3, 50ng/ml) 
and IL-2 (600U/ml) for 2 days then transduced with MIGR1 (36) and the number of 
GFP+ cell measured over time.  
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For Q-PCR, mRNA was isolated using the Qiagen microRNA kit then cDNA was 
prepared using the Invitrogen SuperScript III kit and oligo (dT). Q-PCR reactions were 
run using the SYBR Green PCR Master mix (Applied Biosystems) on a 7900HT Fast 
Real-Time PCR system (Applied Bio- systems). Primer sequences for the following 
genes were: BC055111 (Lem) F: 5’-CGC GCA ACA TCA TGT CC ACC A-3’; R: 5’-
GCC CAA CTT CTG TTC CAG GAA C-3’. gapdh F   5’- ACC ACA GTC CAT GCC 
ATC AC -3’. The sequence for control the control β2-microglubilin gene was from (35). 
For the knock down of Lem mRNA, cytokine cultured CD8 T cells were transduced with 
lentivirus encoding microRNA 30-adapted shRNA (Lem antisense sequence: 5’-TCT 
GCC ATG AGT CTG TCT CG-3’) in the GIPZ shRNAmir-30-GFP vector (GE 
Dharmacon), or scrambled negative control shRNA, at a multiplicity of infection (MOI) 
or 50:1 using manufacturer’s protocol. Cells were then activated for 3 days on anti-CD3 
and anti-CD28 and the % of BrdU cells measured after pulsing from day 1 to day 3.  
 
Protein analysis 
 
Analysis of LEM amino acid sequence predicts the presence of at least two IU 
domains  (GeneSilicoMetaDisorder Service: iicmb.genessilico.pl). Wild-type Lem ORF 
was cloned into pEGTetR as bait by gap repair homologous recombination in yeast Y322 
after co-transformation of the PCR product from amplified ORF (primers: F 5’- CTT 
AAA TGT GAA AGT GGG TCC GAA TTC ATG AGA CCT CGC ACC CAC GG -3’; 
R 5’- CAT AAA TCA TAA GAA ATT CGC CTC GAG TTA AGG AGT AGG ATC 
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TGA ATT GTA GTC C-3’) (24). The bait junction was sequenced to confirm the correct 
reading frame then about 7 x 106 independent cDNA clones from a mouse embryonic 
library were screened in yeast dropout (glucose) medium lacking leucine, histidine, 
trytophan, and uracil. Plasmids were prepared from 23 yeast colonies that can grow on 
the selection plates and expressed lacZ (blue on the X-gal plates). Lem ORF bait was 
transformed into Y322 cells (haploid MATα) and the prey clones into EGY42 (haploid 
MATa), which were then streaked as lines in selection plates (HW/Glu for Y322 and 
L/Glu for EGY42). After 2-3 days, bait strains and prey strains were replicated onto YPD 
plates as columns (bait strains) and rows (prey strains) and incubated overnight at 30oC. 
The intersections of these columns and rows contained diploid yeast formed from haploid 
bait and prey yeast cells. These mated grids were replicated onto two selection plates that 
examined the expression of URA3 (Ura-/glucose + 1 mg/ml 6-AU) and LacZ reporters 
(X-gal/glucose). One pair of known interactors was included as both positive and 
negative controls. Relative interaction strength were estimated with different grades for 
cell growth as a result of URA3 expression, and additionally scored with levels of blue 
intensity on X-gal plates as a function of LacZ expression. Y2H was performed by 
ProteinLinks Inc. 
 
All Western blotting, co-IP and RIP experiments were performed on magnetic bead 
sorted CD8 T cells (Miltenyi Biotech) from the spleens of day 4 LCMV C13 infected 
mice. Western blots (2 x 106 cells) were performed as before (33) using the following 
antibodies: goat anti-BC055111 peptide antibody (sc-245602 Santa Cruz, 1/300 dilution); 
rabbit anti- LEM recombinant protein (in-house, 1/400 dilution); rabbit anti-C1ORF177 
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recombinant protein (Atlas antibodies HPA035890 1/200 dilution); rabbit anti-CRIF1 
(ProteinTech 1620-1-AP 1/300 dilution); rabbit anti-SF2 monoclonal antibody (Abcam 
ab 133689 clone EPR8240, 0.5µg/ml); mouse anti-β actin monoclonal antibody (Abcam 
ab8226 0.4µg/ml) ; goat anti-ND1 peptide antibody (sc-65237 Santa Cruz, 1/200); mouse 
anti-UQCRC2 monoclonal antibody (A11143 Lifetechnologies, 0.4µg/ml); mouse anti-
COX1 monoclonal antibody (A6403 Lifetechnologies, 2µg/ml); mouse anti-ATP5A1 
monoclonal antibody (A21350 Lifetechnologies, 0.5µg/ml); goat anti-MRPL23 (G-13) 
(sc-131603 Santa Cruz, 1/200) then protein G-peroxidase 1/3000 (Sigma-Aldrich).  
Signal strength was measured by densitometry (BioRad Image analyser) and expressed as 
arbitrary units. For co-IP, lysates were prepared from cells (2x107 CD8 T cells) using 
25mM Tris. HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP40, 5% glycerol 
(ThermoScientific) supplemented with 1x protease inhibitor cocktail (Sigma-Aldrich). 
Co-IP was performed with rabbit anti-rLEM antibody (4µg) or rabbit IgG (4µg) coupled 
to amino link resin, according to manufacturer’s procedure (ThermoScientific) followed 
by Western blot  (on 1/10 co-IP material- equivalent to 2x106 cells of input detergent 
extract) to identify LEM-associated proteins. For comparison RNA bound to ASF2 was 
recovered by RIP using anti-ASF2 antibody (3µg) from CD8 T cells using the Imprint 
RNA RIP kit according to manufacturer’s procedure (Sigma Aldrich). Q-PCR on cDNA 
was used to measure the level of Lem mRNA in RIP material.  The Retro mutation  
(A1304G mutation in exon 2) is predicted to abolish an ASF2 binding site in Lem mRNA 
(Wild-type: CAGAAGG to Retro: CAGAGGG)(22). 
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Confocal Immunofluorescence microscopy 
  
LEM/CRIF1 Co-localization: CD8+ T cells (105/well) were purified from C57BL/6 
splenocytes using anti- CD8 MACS beads (Miltenyi Biotech) then cultured with plate 
bound anti-CD3ε (145-2C11 BD Pharmingen) and anti-CD28 (37.51 Biolegend) for 3 
days. Cytospins of CTL were fixed and stained then imaged using a Nikon C1 confocal 
system using standard fixation and staining methods (16).  All primary antibodies were 
used at 1/100. For the secondary antibodies, anti-goat Cy3 was used at 1/400 and anti-
rabbit DyLight 488 at 1/100 (Jackson Immunochemicals). Co-localization of was 
quantified by measuring Pearson’s correlation coefficient of staining for LEM (red) and 
CRIF1 (green) from optical cell slices (n=62) issued from 4 independent experiments.  
Pearson’s correlation coefficient >0.5 is considered strongly correlative. 
 
LEM/CRIF1/Mitochondria co-localization: In vitro generated CTL (as above) were 
stained with Mito Tracker CM-H2 Xros (Molecular Probes) according to manufacturer's 
instructions.  Then incubated on poly-L-Lysine (Sigma-Aldrich) coated coverslips for 1 h 
at 37°C and fixed with 2% PFA-PBS for 10 min at 4°C (105 cells).  Cells were 
permeabilized with 0.1% Triton X in PBS for 5 min at 4° and subsequently blocked with 
2% BSA-PBS for 1 h at RT before staining with rabbit-anti-CRIF-1 (anti-GADD45GIP1 
Proteintech) and goat-anti-BC055111 (Santa Cruz Biotechnology, Inc.) for 1 h at room 
temperature (1/100 dilution). Cells were stained with secondary antibodies ant-rabbit IgG 
Alexa 647 (A21245 Life technologies), anti-goat IgG Alexa 488 (A 11078 Life 
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technologies) (both at 1/400) and DAPI (Sigma Aldrich) for 1 h at room temperature. 
Cells were embedded in ProLong Gold Antifade Mountant (Molecular Probes) then 
examined and photographed with Leica SP8 using a 63x oil immersion objective and 
were analyzed with Volocity (Improvision). MARIS 8.0.2, Huygens Professional 4.2.2 
and FIJI software were used for image processing. FIJI was used to perform image 
handling and necessary format conversions. Huygens Professional 4.2.2 was used to 
deconvolve the images. 3D co-localization analyses were performed using IMARIS 8.0.2 
software (Bitplane; Zurich, Switzerland). Co-distribution of CRIF1 and LEM was 
quantified using pixel-based correlations estimators. Pearson’s correlation coefficients 
(PCC) were measured only in the domains where molecule interaction matters (i.e. inside 
of cells), which was accomplished by using “region of interests” (ROIs). To compute 
PCC values, IMARIS co-localization module was used. To avoid subjectivity CRIF1 and 
LEM thresholds were automatically determined using Costes algorithms. The observed 
correlations have a P-Value = 1.000 within the distribution of random images defined by 
the point spread function width of 0.272 µm (which according to Costes algorithm means 
that 0% of the 200 random images have a larger correlation than the observed one). 
Random images were generated by smoothing white noise with a Gaussian point spread 
function of specified width. 
Metabolic analysis 
 
All metabolic experiments (expect mROS measurements - day 8 see Immunological 
Assays) were performed on magnetic bead sorted CD8 T cells (Miltenyi Biotech) from 
the spleens of day 4 LCMV C13 infected mice. Immuno-capture enzyme assays for 
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OXPHOS complexes I (Abcam ab 109720) and IV (Abcam Ab109878) were performed 
on 5mg of protein extracts using dipstick assays according to manufacturer’s procedure 
(MitoSciences). Oxygen consumption rate (OCR) and Extracellular acidification rate 
(ECAR) was measured using the 24 well Extracellular Flux Analyzer XF24 (Seahorse 
Bioscience) according to the manufacturer’s protocol (37). Cells were equilibrated with 
DMEM lacking bicarbonate and HEPES at 37°C for one hour in an incubator lacking 
CO2. OCR and ECAR were measured followed by sequential treatments with glucose 
(11mM), oligomycin A (5µM), carbonyl cyanide 4-(trifluoromethoxy) phenyl- hydrazone 
(FCCP, 10µM), antimycin A (2µM) + rotenone (2µM) + 2-deoxy-D-glucose (2-DG, 
50mM) (37). Measurements were normalized to cell number in each well. A minimum of 
6 wells representing 6 mice were used per condition in any given experiment.  
To measure OXPHOS gene expression Q-PCR (see above) was used to measure  
mRNA  levels using the following primers(25): Crif1 F: 5’- TAT CTC CTG CGG CTC 
TCT GT-3’, R: 5’-CTT CTG CTT TCG CCA GTT TT-3’, Nd1 F: 5’-ACG CAA AAT 
CTT AGG GTA CA-3’, R: 5’- GAG TGA TAG GGT AGG TGC AA-3’, Uqcrc2 F: 5’-
ATC AAA AGG GGC AAC AAC  AC-3, R: 5’- CAC TCA GGA AGC CCT CTG AC-
3’, Cox1 F: 5’- ATT  CGA GCA GAA TTA GGT CA-3’ R 5’-CTC CGA TTA TTA 
GTG GGA CA-3’,  Atp5a1 F: 5’- AGG CCT ATC CTG GTG ATG TG-3’, R: 5’-CTT 
CAT GGT ACC TGC CAC CT-3’). The relative number of mitochondria per cell the 
ratio of mitochondrial (m) DNA to nuclear (n) DNA measured by determined by 
measuring the ratio of the level of 12SrRNA (mitochondria) to 18SrRNA (nucleus) using 
by Q-PCR (25) using the following primers: 12S F: 5’-GAC AGC TAA GAC CCA AAC 
TG-3’, R: 5’-TTA GCA AGA GAT GGT GAG GT-3’, 18S F: 5’- TCA TAA GCT TGC 
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GTT GAT TA- 3’ R: 5’- TAG TCA AGT TCG ACC GTC TT-3’. Mitochondrial mass 
was determined by staining of surface stained cells with MitoTracker green FM (38).  
 
Statistics 
 
Significant differences were determined using two-tailed student t-tests. For survival 
curves Geha-Breslow-Wilcoxon tests were used to determine significant differences. For 
CIM co-staining Pearson’s correlation coefficients were determined 
.  
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Fig. S1. 
a. The Retro mutation has a semi-dominant phenotype. Retro homozygous (R/R) were 
back-crossed with WT C57BL/6 mice (WT/WT) to produce Retro heterozygous (WT/R) 
mice. Mice were infected with LCMV C13 then on day 8 p.i.  the level of np396+ CD8+ 
cells was determined in the spleen. p<0.05,  **p<0.005, ***p<0.0005. Two-tailed student 
t-tests were used. Each data set is representative of at least 4 individual experiments. b. 
Increased levels of IFN-γ producing CD8 T cells in Retro mutant mice. Mice were 
infected with LCMV C13 then on day 8 p.i. 8 splenocytes were re-stimulated with either 
gp 33 or np 396 peptide then CD8 + cells stained for intracellular IFN-γ. The level of 
IFN-γ of CD8 T cells was also determined in un-infected WT mice (right hand data 
points). Shown are the means ± sem (n=3 mice). Two-tailed student t-tests were used. 
Each data set is representative of at least 2 individual experiments. c. CTL activity 
normalized for frequency of LCMV-specific CD8 T cell. Mice were infected with LCMV 
C13 on day 8 p.i. the frequency of np396+ CD8+ determined (CTL). Target (T) cells 
pulsed with np 396 peptide were incubated with CTL at various ratios and specific lysis 
measured. Mean ± sem (n=5 mice). Each data set is representative of at least 2 individual 
experiments. 
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Fig. S2 
Increase in activated phenotype  (CD44hi) T cells in Retro mutant mice. Histogram for % 
CD44hi of either CD8+ or CD4+ cells in the spleens of wild-type (W) or Retro mutant 
mice.   Mean ± sem,  n= 6 mice) *** p<0.0001, ** p<0.001. Two-tailed student t-tests 
were used. Each data set is representative of at least 3 individual experiments.  
 
  
Fig S2. Blood and lymphoid populations in Retro mutant mice.  14 month old C57BL/6 wild-type (W) or Retro (R) 
mutant mice were analyzed. (a) Leukocyte levels were determined by flow-cytometry of peripheral blood (b) Lymphocyte 
levels from peripheral blood leukocytes (PBL), bone marrow (BM), liver, lymph-node (LN), spleen and lung determined by 
staining for B220, CD3, CD8 and CD3 surface makers. Mean +/- sem. (c). Histogram for % CD44hi of either CD8+ or CD4+ 
cells in the spleens.  ( mean ± sem,  n= 6 mice) *** p<0.0001, ** p<0.001. 
 
(n=4-6) Wild-type        Retro Wild-type     Retro 
PBL  LN 
% CD8 15.6 +/-0.6 16.6 +/-1.1 % CD8 24.9 +/-0.9 24.3 +/-0.8 
%CD4 18.7+/-1.1 20.4+/-1.5 %CD4 38.2+/-1.2 40.7+/-0.7 
%B220 37.0+/-1.0 36.6+/-4.5 %B220 23.5+/-1.1 21.4+/-1.5 
BM  Spleen 
% CD8 1.1 +/-0.1 0.7 +/-0.1 % CD8 8.3 +/-0.4 9.1 +/-0.8 
%CD4 1.6+/-0.1 1.5+/-0.2 %CD4 21.0+/-1.0 24.0+/-1.0 
%B220 24.0+/-1.6 26.6+/-0.1 %B220 56.0+/-1.1 55.0+/-1.3 
Liver  Lung 
% CD8 11.4 +/-0.8 12.0 +/-0.2 % CD8 9.6 +/-0.5 10.2 +/-0.8 
%CD4 42.7+/-2.6 43.5+/-1.1 %CD4 15.2+/-0.9 16.2+/-1.1 
%B220 11.1+/-1.7 14.6+/-2.0 %B220 14.2+/-0.7 15.0+/-0.55 
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Fig. S3 
Anti-double stranded (ds) DNA antibodies in the serum of WT and Retro mutant (R). 
Titer is represented as Arbitrary ELISA Unit (AEU)/ml from a standard curve of anti-ds 
DNA antibody. (n=4-5 mice). Two-tailed student t-tests were used. . Each data set is 
representative of at 2 individual experiments.  
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Fig. S3. Auto-antibodies in Retro mutant mice. 14 month old C5BL/6J wild-type (W)  or Retro mutant mice (R) were 
examined for (a) the deposition of IgG or C3 complement in kidney glomeruli or arteries  using immunofluorescence to 
score extent of staining (0-5 range). Mice were scored blindly. (b) anti-double stranded (ds) DNA antibodies in the serum 
using ELISA .  Titer is represented as Arbitrary ELISA Unit (AEU)/ml from a standard curve of anti-ds DNA antibody. (n=4-5 
mice). P=0.43.  
a b 
 
 
17 
 
 
 
Fig. S4 
 The Retro mutation acts directly on CD8 T cells and also increases memory responses. a. 
Adoptive transfer experiment. b. Mean number of donor WT or Retro mutant (R) np396+ 
CD8+ splenocytes. c. ex vivo CTL activity. d.  LCMV C13 Titer. Number of np396+ 
CD8+ (e) and (f) gp33+ CD8+ Tcm splenocytes on day 70 after acute infection with 
LCMV Armstrong. Mice were re-infected with LCMV Armstrong  then after 5 days the 
number of secondary np396+ CD8+ (g) and gp33+ CD8+ (h) splenocytes determined. 
Mean ± sem, n=6-10 mice. Each data set is representative of at least 3 individual 
experiments. ***p<0.0005, **p<0.001. Two-tailed student tests were used.  
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Fig. S4.  Retro mutation acts directly on CD8 T cells and also increases memory responses. a. Adoptive transfer 
experiment. b. Mean number of donor WT or Retro mutant (R) np396+ CD8+ splenocytes. c. ex vivo CTL activity. d.  LCMV 
C13 Titer.! Number of np396+ CD8+ (e) and (f) gp33+ CD8+ Tcm splenocytes after acute infection with LCMV Armstrong. 
Number of secondary np396+ CD8+ (g) and gp33+ CD8+ (h) splenocytes. Mean ± sem, n=6-10 mice. Each data set is 
representative of at least 3 individual experiments. ***p<0.0005, **p<0.001. Two-tailed student tests were used.  
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Fig.S5 
Memory Precursors in Retro mutant mice. Levels of memory precursors (MP: KLRG1lo 
CD127+ of either gp33+ CD8+ or np396+ CD8+ cells) and short-lived effectors (SLE: 
KLRG1hi CD127- of either gp33+ CD8+ or np396+ CD8+ cells) were determined in 
peripheral blood leukocytes (PBL) or spleen of wild-type (WT) or Retro mutant (R) mice 
after infection with LCMV Armstrong (2x105 pfu i.p.). Scatter plots are from day 21  
after infection. (n=3 mice of each type ± sem). Each data set is representative of at least 3 
individual experiments.*p<0.05, ** p<0.025. Two-tailed student tests were used.  
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Fig. S5. Memory Precursors in Retro mutant mice. Levels of memory precursors (MP: KLRG1lo CD127+ of either  
gp33+ CD8+ or np396+ CD8+ cells) and short-lived effectors (SLE: KLRG1hi CD127- of either gp33+ CD8+ or np396+ CD8+ cells) were 
 determined in peripheral blood leukocytes (PBL) or spleen of wild-type (W) or Retro mutant (R) mice after infection with LCMV  
Armstrong ( 2x105 pfu i.p.). Scatter plots are from day 21  after infection. (n=3 mice of each type ± sem).  
Each data set is representative of at least 3 individual experiments.*p<0.05, ** p<0.025. Two-tailed student tests were used.  
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Fig.S6 
SNV associated with the Retro phenotype. a. Shown are the 8 homozygous SNV in the 
coding sequence of genes (CDS) after comparing the whole exome of DNA from a Retro 
homozygous mutant  mouse  (Variant –V) with the reference C57BL/6J sequence from 
NCBI (Reference –R). The sequence number on the relevant chromosome is indicated. 
The number of sequencing reads covering the SNV is indicated (Reads). All mutations 
were non-synonomous (amino acid substitution) expect for the SNP in Ppig that resulted 
in a putative STOP codon. Indicated in yellow are the 4 SNV that were not found in the 
parental C57BL/6J strain (Charles River sub-strain) used for the ENU-mutagenesis and 
so are associated with the Retro line. b. The four Retro-associated SNVs were each 
present on different chromosomes and so we determined which segregated with the Retro 
homozygous mutant phenotype after LCMV C13 infection of the progeny of 
heterozygote inter-crosses.   Shown are the genotypes for 10 progeny of the intercross of  
Retro heterozygous mice which exhibited a Retro  homozygous phenotype (> 6-fold 
higher level of splenic np396+ CD8+ cells compared to WT on day 8 after  infection). 
Mutant Retro alleles (r) and wild-type alleles (+) are indicated 
 
 
 
Fig. S6. SNV associated with the Retro phenotype (a) Shown are the 8 homozygous SNV in the coding sequence of 
genes (CDS) after comparing the whole exome of DNA from a  Retro homozygous mutant  mouse (line 1) (Variant –V) with 
the reference C57BL/6J sequence from NCBI (Reference –R). The sequence number on the relevant chromosome is 
indicated. The number of sequencing reads covering the SNV is indicated (Reads). All mutations were non-synonomous 
( amino acid substitution) expect for the SNP in Ppig that resulted in a putative STOP codon. Indicated in yellow are the 4 
SNV that were not found in the parental C57BL/6J strain (Charles River sub-strain) used for the ENU-mutagenesis and so 
are associated with the Retro line. (b).!The four Retro-associated SNVs were each present on different chromosomes and so 
we determined which segregated with the Retro homozygous mutant phenotype after LCMV C13 infection of the progeny of 
heterozygote inter-crosses.   Shown are the genotypes for 10 progeny of the intercross of  Retro heterozygous mice which 
exhibited a Retro  homozygous phenotype (> 6-fold higher level of splenic np396+ CD8+ cells compared to wild-type on day 8 
after  infection). Mutant Retro alleles (r) and wild-type alleles (+) are indicated 
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Fig.S7 
The Retro mutation and its effect on CTL response to LCMV C13. a. Sequence of exon 2 
region of BC055111 reveals an A to G mutation at position 1304 in WT compared to 
Retro (R) homozygous mutant mice. Mice were infected with LCMV C13 then on day 8 
p.i. b.  Number of np396+ CD8+ splenocytes.  c.  LCMV titer and d. % specific CTL lysis. 
Each data set is representative of at least 3 individual experiments. .  ***p<0.005, 
**p<0.03, *p<0.05. Two-tailed student tests were used.  
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Fig. S7. Retro mutation and it’s effect on CTL response to LCMV C13. a. Sequence of exon 2 
region of BC055111 reveals an A to G mutation at position 1304 in WT compared to Retro (R) 
homozygous mutant mice. Mice were infected with LCMV C13 then on day 8 then b.  Number of 
np396+ CD8+ splenocytes.  c.  LCMV titer and d. % specific CTL lysis were determined. Each data 
set is representative of at least 3 individual experiments. .  ***p<0.005, **p<0.03,! *p<0.05. Two-
tailed student tests were used.  
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Fig.S8 
Generation of mice harboring BC055111 KO allele. a. The BC055111 tm1a (KOMP)Wtsi  allele 
is predicted to be a null allele through splicing to a lacZ trapping element contained in the 
targeting cassette. The trapping cassette includes the mouse En2 splice Acceptor (En2 
SA) and SV40 poly adenylation (pA) signals, which are highly effective in creating null 
alleles in mice. Position of the PCR primers is shown by red arrows as is the expected 
size of the PCR product  (Forward: within pA of neo, Reverse outside of 3’ homology 
arm in between exon 8 and 9). b. Validation of the BC055111 tm1a (KOMP)Wtsi  allele by long 
range PCR on DNA from two ES clones harboring BC055111 targeted alleles (C02 and 
H01) yielded product with the expected size. PCR on no-template control (NTC) or WT 
did not give a PCR product.  
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Fig.S9 
Expression of LEM from synthetic ORFs. The purpose of this experiment was to 
determine if the Retro mutation in the Lem gene affects the qualitative function of the 
LEM protein. We predict that the Retro mutation (A1304) would make an E to G 
substitution in amino acid 50 of LEM (E50G mutation). We generated synthetic open 
reading frames (ORF) (lacking introns and un-translated mRNA sequences), 
corresponding to the WT or Retro mutant gene sequences, under the control of a 
transgenic promoter. Western Blots on SDS total cell extracts (0.5mg) from CTLL-2 cells 
transduced independently with either MIGR1 encoding ORFs with either WT (WT-1, 
WT-2, WT-3) or Retro mutant  (R-1, R-2, R-3) coding sequences.  Westerns were probed 
with goat- BC055111 antibody then protein G-HRP. We detected equal intensity bands in 
all batches of transduced CTLL-2 cells. Therefore the Retro mutation had no effect on the 
expression of LEM encoded by the synthetic ORFs in MIGR1 retroviruses. We found 
that the ability of the ORF with the Retro sequence was no better than wild-type at 
driving the proliferation of CTLL-2 cells after culture with IL-2 (Fig. 3j). Therefore, we 
conclude that the putative E50G mutation in LEM does not increase the ability of LEM to 
drive T cell proliferation. Rather, we conclude that increased expression of LEM in Retro 
mutant cells is responsible for increased proliferation. In other words, the Retro mutation 
has a quantitative rather than a qualitative effect on LEM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.S9. Expression of LEM from synthetic ORFs. The purpose of this experiment was to determine if the Retro mutation in 
the Lem gene affects the qualitative function of the LEM protein. We predict that the Retro mutation (A1304) would make an 
E to G substitution in amino acid 50 of LEM (E50G mutation). We generated synthetic open reading frames (ORF) (lacking 
introns and un-translated mRNA sequences), corresponding to the WT or Retro mutant gene sequences, under the control of 
a transgenic promoter. Western Blots on SDS total cell extracts (0.5mg)  from CTLL-2 cells transduced independently with 
either MIGR1 encoding ORFs with either wild-type (WT-1, WT-2, WT-3) or Retro mutant  (R-1, R-2, R-3) coding sequences.  
Westerns were probed with with goat- BC055111 antibody then protein G-HRP. We detected equal intensity bands in all 
batches of transduced CTLL-2 cells. Therefore the Retro mutation had no effect  on the expression of LEM encoded by the 
synthetic ORFs in MIGR1 retroviruses. 
 
We fou  that the ability of the ORF with the Retro sequenc  was no better than wild-type at driving the proliferation of 
CTLL-2 cells after culture with IL-2 (Fig. 3j). Th refore, we conclude that the putative E50G mutation in LEM does not 
increase the ability of LEM to driv  T cell prolif ration. Rather, w  conclude that increased expression of LEM in Retro mutant 
cells is responsible for increased prolifera ion. In ther w rds, the R tro mutation has a quantitative rather than a qualitative 
ffect on .!!
!
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Fig. S10 
Rabbit anti-recombinant LEM antibody. a. Western Blots. SDS total cell extracts (0.5mg) 
from CTLL-2 cells transduced with either MIGR1 encoding wild-type (W) or Retro 
mutant LEM (R) (Fig. 3j) were probed with rabbit anti-recombinant LEM antibody 
(0.2mg/ml) then protein G-HRP. We detected a strong band corresponding to LEM in 
CTLL-2 cells expressing transgenic WT or R LEM and a weaker endogenous band in 
vector alone transduced cells. The anti-LEM antiserum was then used for co-IP 
experiments. Upper panel – long exposure, bottom panel –  short exposure. b. 
Intracellular staining and flow-cytometry on CTLL-2 cells expressing LEM (WT) (dark 
histogram) or vector-transduced CTLL-2 cells (light histogram) were stained with anti-
LEM (1/1000) then anti-rabbit IgG APC (1/1000). Mean fluorescence levels for each 
histogram are indicated in top right corner. c. Intracellular staining and flow-cytometry 
with either pre-immune or anti-LEM antibody (each 1/1000) on day 3 WT CD8 T cells 
after activation on anti-CD3/CD28. The % positive is indicated. d. Intracellular staining 
and flow-cytometry for LEM on CD44lo CD62Lhi CD8+ cells (light histogram) or   
CD44hi CD62Llo CD8+ (dark histogram) splenocytes on day 2 after infection of Retro 
mutant mice with LCMV C13. Mean fluorescence levels for each histogram are indicated 
in top right corner.  
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Fig. S11 
Effect of LEM expression on levels of activated CD8 T cells. WT and Retro mutant (R) 
mice were infected with LCMV C13  a. Mean number of np396+ CD8+ splenocytes. b. 
Mean number of CD44hi CD62Llo CD8+ splenocytes (activated CD8 T cells). c. Mean 
number of CD44lo CD62Lhi CD8+ splenocytes (naïve CD8 T cells). WT and Retro lines 
overlap. Mice were infected with LCMV Armstrong. MFI of anti-LEM staining on (c) 
CD44hi CD62Llo CD8+ or (d) np396+ CD8+ splenocytes. f. MFI of PD-1 staining for 
naive CD8 T cells or after anti-CD3 antibody activation g % PD-1+. Each data set is 
representative of at least 3 individual experiments. . Mean ± sem (n=4-6 mice). *** 
p<0.001; ** p<0.005, * p<0.01. Two-tailed student tests were used. The number of 
activated CD8 T cells (Fig. S11b) and np396+ CD8+ cells (Fig. S11a) but not naïve CD8 
T cells (Fig. S1c) were increased in Retro mutant compared to WT mice after LCMV 
C13 infection. After acute infection of WT mice with LCMV Armstrong, LEM was 
maximally up-regulated in day 4 activated CD8 T cells (Fig. S11d).  LEM was up-
regulated in LCMV np396-specific CD8 T cells in both day 8 effectors and day 30 and 70 
memory CD8 T cells (Fig. S11e). There was no difference in either PD-1 level (Fig.S11f) 
or % PD-1+ (Fig. S11g) after in vitro TCR stimulation of Retro mutant compared to WT 
purified CD8 T cells.  
 
 
 
Fig. S11. Effect of LEM expression on levels of activated CD8 T cells. WT and Retro mutant (R)  mice were infected with 
LCMV C13  a. Mean number of np396+ CD8+ splenocytes. b. M an number of CD44hi CD62Llo CD8+ splenocytes (activated 
CD8 T cells). c. M an number of CD44lo CD62Lhi CD8+ splenocytes (naïve CD8 T cells). Mice were infected with LCMV 
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student tests were used. The number of np396+ CD8+ cells (Fig. S11a) and  activated CD8 T cells (Fig. S11b)  but not naïve 
CD8 T cells (Fig. S11c) were increased in Retro mutant compared to WT mice after LCMV C13 infection. After acute infection 
of WT mice with LCMV Armstrong, LEM was maximally up-regulated in day 4 activated CD8 T cells (Fig. S11d).  LEM was up-
regulated in LCMV np396-specific CD8 T cells in both day 8 effectors and day 30 and 70 memory CD8 T cells (Fig. S11e). 
There was no difference in either PD-1 level (Fig.S11f) or % PD-1+ after in vitro TCR stimulation of Retro mutant compared to 
WT purified CD8 T cells.  
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Fig. S12 
In vitro proliferation of CD8 T cells requires LEM expression. a. Flow cytometry 
histograms showing % BrdU positive CD8 T cells from WT and R mice after 3 days of 
culture on anti-CD3 and anti-CD28 antibodies. Cells were pulsed with BrdU from day 1 
to day 3. Bar graph of Mean +/- sem (n=4 mice) % BrdU. b. Western blot for LEM or 
β−actin on WT or R CD8 T cells transduced with lentivirus encoding shRNA specific for 
lem message or scrambled (sc) control after culture with IL-2, IL-7 and IL-15 (all at 
100ng/ml). Histogram for mean signal strength +/- sem (n=4 transductions). c. 
Transduced cells were activated on anti-CD3 and anti-CD28 antibodies for 3 days and % 
BrdU determined . Cells were pulsed with BrdU from day 1 to day 3.  Bar graph for mean 
± sem (n=4 transductions). Each data set is representative of at least 3 individual 
experiments. ***p<0.0001, ** p<0.005, *p<0.05. Two-tailed student tests were used.  
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Fig.S13 
Yeast two-hybrid analysis on LEM. A. Bait strains and prey strains were replicated onto 
YPD plates as columns (bait strains) and rows (prey strains) and incubated overnight at 
30oC. The intersections of these columns and rows contained diploid yeast formed from 
haploid bait and prey yeast cells. These mated grids were replicated onto two selection 
plates that examined the expression of URA3 (Ura-/glucose + 1 mg/ml 6-AU) and LacZ 
reporters (X-gal/glucose). One pair of known interactors was included as both positive 
and negative controls. Relative interaction strength were estimated with different grades 
for cell growth as a result of URA3 expression, and additionally scored with levels of blue 
intensity on X-gal plates as a function of LacZ expression. 22 bait clones were identified. 
b. The intensity of β-gal staining is indicated by the number of stars. Several genes are 
represented by multiple clones.  
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Fig. S14 
Co-localization of LEM and CRIF1. CIM images of 3 different activated T cells were 
subjected to 1-D analysis green (CRIF1) and red fluorescence (LEM) signal intensity. 
Bar = 2.5µm. Five positions (6-44) were selected along a given white scan line (arrow 
indicating direction) and the red and green signal measured. Correlation between strength 
of red and green signal along a scanned line was determined by calculated the Pearson’s 
correlation coefficent.r2>0.5 is considered strongly correlative. For each experiment >60 
optical slices were examined. Shown is data from one of three experiments. All three 
experiments had mean Pearson’s correlation coefficents >0.5.  
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Fig. S14 Co-localization of LEM and 
CRIF1. CIM images of  3 different activated 
T cells were subjected to 1-D analysis green 
(CRIF1) and red fluorescence(LEM)  signal 
intensity. Bar = 2.5µm. Five positions (6-44) 
were selected along a given white scan line 
(arrow indicating direction) and the red and 
green signal measured. Correlation between 
strength of red and green signal along  a 
scanned line was determined by calculated 
the Pearson’s correlation coefficent.r2>0.5 is 
considered strongly correlative. For each 
experiment >60 optical slices were exam 
ined. Shown is data from one of three 
experiments. All three experiments has 
mean Pearson’s correlation coefficents >0.5.  
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Fig.S15 
Staining of CTL for LEM and CRIF1 in the mitochondria. Top.  High power CIM images 
of a CTL stained with DAPI (blue) for nuclei or mitotracker red (MitoT) for 
mitochondria and antibodies against LEM and CRIF1. Overlay between LEM (green) and 
CRIF1 (violet) is indicated by white, LEM and MitoT (red) by yellow/orange, CRIF1 and 
MitoT by purple.  Bar= 2.5µm. Bottom. Low power CIM images of multiple CTL stained 
as above. Bar= 10µm. Each data set is representative of at least 2 individual experiments. 
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Fig. S15 Co-localization of LEM and CRIF1 in the mitochondria. a.  High power CIM images of a CTL stained with DAPI 
(blue)  for nuclei or mitotracker red (MitoT) for mitochondria and antibodies against LEM and CRIF1. Overlay between LEM 
(green) and CRIF1 (violet) is indicated by white, LEM and MitoT (red) by yellow/orange, CRIF1 and MitoT by purple.  Bar= 
2.5µm. b. Low power CIM images of multiple CTL stained as above. Bar= 10µm. Each data set is representative of at least 2 
individual experiments. 
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Fig. S16.  
Co-distribution of CRIF1 and LEM. Distribution of Pearson’s correlation coefficients 
(PCC) for CTL stained with DAPI, CRIF1, LEM and Mitotracker red (Fig. S15). Co-
localization was performed on 7 datasets each with 20 Z-planes (N=140 images). A total 
of 70 cells were examined for the whole experiment. The PCC for LEM/Mitotracker red 
and CRIF1/Mitotracker and the analysis supports co- distribution of both proteins in 
mitochondria. In addition PCC indicate that CRIF1 but not LEM is located in the nucleus. 
Blocks indicate the range of PCC and are ± sem. 
 
   
When it comes to co-distributions, the Pearson’s Correlation Coefficient (PCC) indicates a co-distribution of CRIF1 and 
LEM in entire cell (avg. PCC=0.59), smaller value is observed for mitochondria (avg. PCC=0.34). The result is robust since 
Costes algorithm for threshold selection was used (returning a P-value of 1.0 for the proposed test). More technical details 
in method section below. To test if the method works as expected a negative control was constructed - PCCs for DAPI 
and LEM (as we expect these two signals are not correlated and PCCs are around 0). I would suggest to include only the 
result for entire cells in the final text.  
Numerical data used to create plots are provided in .csv files together with the report. 
DELIVERABLE 2: TEXT 
Here you can find proposed text for the main and supplementary part of the article. 
Main text 
CRIF1 is required for translation of subunits of oxidative phosphorylation complexes (OXPHOS) I, III and IV 
through interaction with nascent OXPHOS proteins and the 39S subunit of the mitoribosome in the inner 
membrane (IM) of mitochondria (32). Confocal immunofluorescence microscopy (CIM) on CTL revealed that 
LEM and CRIF1 are both significantly more abundant in mitochondria than in cytoplasm or nuclei of activated T 
cells (Fig. SX). Additionally correlation studies on several T cells (N=70) suggest co-distribution of LEM with 
CRIF1 within the cells (mean Pearson’s correlation coefficient for regions of images containing cells is equal to 
0.59; Fig. SY). 
Mitochondria 0.4453 0.2681 0.2963 0.5849 0.3837 0.5523 0.255
En7reCell 0.385 0.4886 0.6072 0.6469 0.5859 0.684 0.6072
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Fig .S17 
LEM and mitochondrial activity. In all experiments CD8 T cells were from mice on day 4 
p.i. with LCMV C13. a. Real-time PCR measurement of mRNA for genes encoding 
mitochondrial proteins. Shown is the mean (+/-) sem (n=6 mice) of mRNA relative to the 
WT (WT/WT). There was no statistical difference between WT and Retro mutant (R/R) or 
LEM heterozygous KO (W/KO). b. Number of mitochondria determined by the ratio of 
mtDNA to nDNA determined by real-time PCR for mitochondrial and nuclear rRNA 
genes. Shown is the mean (+/-) sem (n=6 mice). There was no statistical difference 
between WT and Retro mutant (R/R) or LEM heterozygous KO (WT/KO). c.  Mass of 
mitochondria per CTL measured by mean fluorescence intensity (MFI) staining with 
Mitotracker. Shown is the mean ± sem (n=6 mice). There was no statistical difference 
between WT and Retro mutant (R/R) or LEM heterozygous KO (WT/KO). d and e. 
Glycolysis was measured by Extracellular Acidification Rate (ECAR) and initiated by the 
injection of glucose then oligomycin (oligo) to reach maximal ECAR (t=35min). 
Glycolysis was terminated by injection of 2-deoxyglucose (2-DG) (t=119min). Shown is 
the mean ± sem (n=6 mice). Each data set is representative of at least 3 individual 
experiments. Two-tailed student t-tests were used  
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Fig. S16. LEM and mitochondrial activity. (a) Real-time PCR measurement of mRNA for genes encoding mitochondrial proteins. 
Shown is the mean (+/-) sem (n=6 mice) of mRNA relative to the WT(WT/WT) from CD8 cells recovered after 4 days of infection 
LCMV C13. There was no statistical difference between wild-type and Retro mutant (R/R) or LEM heterozygous KO (W/KO).(b) 
Number of mitochondria determined by the ratio of mtDNA to nDNA determined by real-time PCR for mitochondrial and nuclear rRNA 
genes. Shown is the mean (+/-) sem (n=6 mice). There was no statistical difference between WT and Retro mutant (R/R) or LEM 
heterozygous KO (WT/KO).(c)  Mass of mitochondria per CTL measured by mean fluorescence intensity(MFI) after staining with 
Mitotracker. Shown is the mean ± sem (n=6 mice). There was no statistical difference between wild-type and Retro mutant (R/R) or 
LEM heterozygous KO (WT/KO).(d and e) Glycolysis was measured by Extracellular cidification Rate (ECAR) and initiated by the 
injection of glucose then oligomycin (oligo) to reach maximal ECAR(t=35min). Glycolysis was terminated by injection of 2-
deoxyglucose (2-DG) (t=119min). Shown is the mean ± sem (n=6 mice). Each data set is representative of at least 3 individual 
experiments.  
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Fig. S18 
Effect of Crif-AS on expansion of CD8 T cells. a. Cytokine cultured CD8 T cells were 
transduced with MIGR1 retrovirus encoding Crif1-AS or vector alone then equal 
numbers of GFP + cells (5x106) were adoptively transferred to C57BL/6 recipient mice. 
b. Western blot on GFP+ CD8 T cells transduced with MIGR1 vector alone (vector) or 
MIGR1 encoded Crif1-AS after adoptive transferred and infection with LCMV C13. Bar 
graph for signal strength. There was about an 80% knock-down in CRIF1 expression. c. 
Histograms for the percentage of GFP+ cells on gated CD8+ cells from the spleens of 
mice on day 8 p.i. with LCMV C13. Top left histogram is from an infected recipient mice 
that did not receive GFP+ CD8 T cells. Percentage GFP+ is shown in top right corner. Bar 
graph for mean % BrdU d, or e number of donor GFP+ cells transduced with either vector 
alone or Crif1-AS. % BrdU fold-increase in R over WT: V = 3 Crif1-AS = 0; number 
GFP+ cells fold-increase in R over WT: V = 10, Crif1-AS  = 2. Mean ± sem (n=6 mice). 
These data representative of 3 independent experiments. **p<0.005, ***p<0.0005. Two-
tailed student tests were used.  
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Fig. S19 
Model for LEM function in mitochondria. LEM associates with CRIF1 as part of a 
complex that includes 39S subunit of the mitoribosome and OXPHOS polypeptides (pp). 
LEM facilitates the insertion of nascent OXPHOS polypeptides into the inner membrane 
(IM) of the mitochondrion. OXPHOS activity results in the production of ROS in 
mitochondria (mROS), which leads to T cells activation. LEM expression is induced by 
both TCR and cytokine signals.  
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Fig. S17. Model for LEM function in mitochondria .!!!. !
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Table S1. 
Blood and lymphoid populations in Retro mutant mice. Leukocyte levels were 
determined by flow-cytometry of peripheral blood. 14 month old C57BL/6 WT or Retro 
mutant mice were analyzed.  Each data set is representative of at least 3 individual 
experiments.  
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Table S2. 
Lymphocyte levels from peripheral blood leukocytes (PBL), bone marrow (BM), liver, 
lymph-node (LN), spleen and lung determined by staining for B220, CD3, CD8 and CD3 
surface makers. 14 month old C57BL/6 wild-type or Retro mutant mice were analyzed. 
Mean +/- sem (n=4-6 mice). Each data set is representative of at least 3 individual 
experiments.  
  
(n=4-6) Wild-type        Retro Wild-type     Retro 
PBL  LN 
% CD8 15.6 +/-0.6 16.6 +/-1.1 % CD8 24.9 +/-0.9 24.3 +/-0.8 
%CD4 18.7+/-1.1 20.4+/-1.5 %CD4 38.2+/-1.2 40.7+/-0.7 
%B220 37.0+/-1.0 36.6+/-4.5 %B220 23.5+/-1.1 21.4+/-1.5 
BM  Spleen 
% CD8 1.1 +/-0.1 0.7 +/-0.1 % CD8 8.3 +/-0.4 9.1 +/-0.8 
%CD4 1.6+/-0.1 1.5+/-0.2 %CD4 21.0+/-1.0 24.0+/-1.0 
%B220 24.0+/-1.6 26.6+/-0.1 %B220 56.0+/-1.1 55.0+/-1.3 
Liver  Lung 
% CD8 11.4 +/-0.8 12.0 +/-0.2 % CD8 9.6 +/-0.5 10.2 +/-0.8 
%CD4 42.7+/-2.6 43.5+/-1.1 %CD4 15.2+/-0.9 16.2+/-1.1 
%B220 11.1+/-1.7 14.6+/-2.0 %B220 14.2+/-0.7 15.0+/-0.55 
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Table S3. 
Auto-antibodies in Retro mutant mice. Five (1-5) 14 month old C5BL/6J wild-type or 
Retro mutant mice were examined for the deposition of IgG or C3 complement in kidney 
glomeruli or arteries using immunofluorescence to score extent of staining (0-5 range). 
Mice were scored blindly. There was no significant difference in the scores between WT 
and Retro mutant mice. 
 
